US5326559A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules
Assignee: Individual
•
Filing: 1991-05-16
•
Granted: 1994-07-05
•
Expires: 2011-05-16
Abstract
Abstract The invention features a method for treating a patient suffering from accelerated atherosclerosis in a patient suffering from vascular damage, e.g., damage caused by percutaneous transluminal coronary angioplasty (PTCA), heart transplantation, or coronary vein graft. The method includes administering to the patient a molecule which is capable of specifically binding to a interleukin receptor expressed on a cell of the patient which contributes to the process of accelerated atherosclerosis. The molecule is capable of decreasing the viability of the cells.
Inventors
- 👤 D. Douglas Miller
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 00:57
CPC Classifications
C; C07; C07K; C07K19/00; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/62; C07K14/00; C07K14/435; C07K14/52; C07K14/54; C07K14/5406; C07K14/5412; C07K14/55; A61K38/00; C07K2319/00; C07K2319/55; C07K2319/70; C07K2319/74; C07K2319/75
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
101 words
A method for inhibiting accelerated atherosclerosis in a patient suffering from vascular injury, said method comprising administering to said patient a molecule which is capable of specifically binding to an interleukin-2 receptor expressed on a cell of said patient which contributes to the process of accelerated atherosclerosis, said molecule being capable of decreasing the viability of said cell, said molecule being a hybrid molecule comprising a first and a second portion joined together covalently, said first portion comprising a cytotoxin capable of decreasing cell viability and said second portion comprising interleukin-2 or an antibody capable of binding to the interleukin-2 receptor.
Claim 2
Independent Claim
101 words
A method for inhibiting accelerated atherosclerosis in a patient suffering from vascular injury, said method comprising administering to said patient a molecule which is capable of specifically binding to an interleukin-2 receptor expressed on a cell of said patient which contributes to the process of accelerated atherosclerosis, said molecule being capable of decreasing the viability of said cell, said molecule being a hybrid molecule comprising a first and a second portion joined together covalently, said first portion comprising a cytotoxin capable of decreasing cell viability and said second portion comprising interleukin-2 or an antibody capable of binding to the interleukin-2 receptor.
Claim 3
Dependent Claim
11 words
The method of claim 1 wherein said cell is a lymphocyte.
Claim 4
Dependent Claim
15 words
The method of claim 1 wherein said interleukin-2 receptor is a high affinity interleukin-2 receptor.
Claim 5
Dependent Claim
13 words
The method of claim 1 wherein said vascular injury is caused by angioplasty.
Claim 6
Dependent Claim
15 words
The method of claim 1 wherein said vascular injury is caused by coronary vein graft.
Claim 7
Dependent Claim
15 words
The method of claim 1 wherein said vascular injury is caused by cardiac transplant surgery.
Claim 8
Dependent Claim
14 words
The method of claim 1 wherein said molecule kills cells bearing said interleukin-2 receptor.
Claim 9
Dependent Claim
29 words
The method of claim 1 wherein said cytotoxin is a fragment of a peptide toxin which is enzymatically active but which does not possess generalized eukaryotic receptor binding activity.
Claim 10
Dependent Claim
32 words
The method of claim 8 wherein said fragment of a peptide toxin comprises fragment A of diphtheria toxin and enough of fragment B of diphtheria toxin to facilitate translocation into the cytosol.
Claim 11
Dependent Claim
12 words
The method of claim 9 wherein said molecule is DAB 389 IL-2.
Claim 12
Dependent Claim
12 words
The method of claim 9 wherein said molecule is DAB 486 IL-2.
References Cited (Backward Citations)
EP0396387A2
Cited
WO1991001004A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-07-04 | 1998-01-03 | 1998-07-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-07-04 | 2002-01-03 | 2002-07-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-07-04 | 2006-01-03 | 2006-07-05 | $7700.00 | Window Closed / Lapsed |